Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary phage-based platform, ImmunoPhage, that enables the rapid generation of immune activating agents that fully engage the immune system. Using its proprietary ImmunoPhage platform, Sensei is developing a library of ImmunoPhage called Phortress targeting multiple tumor associated antigens to treat patients using a personalized yet off the shelf cocktail approach.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/21 | $30,000,000 | Series B |
Apeiron Investment Group Cambrian Biopharma Catalio Capital Management Future Ventures Moore Strategic Ventures Presight Captial Pura Vida Investments | undisclosed |
